Table 1 Characteristics of the study cohort. Number of patients classified according to PAM50 subtypes (Basal, HER2, Luminal A or Luminal B), estrogen receptor, progesterone receptor and HER2 receptor status
From: Refinement of breast cancer molecular classification by miRNA expression profiles
n | ||||
|---|---|---|---|---|
Basal | ER- | HER2- | PR- | 45 |
Basal | ER- | HER2+ | PR- | 4 |
Her2 | ER- | HER2- | PR- | 1 |
Her2 | ER- | HER2+ | PR- | 29 |
Her2 | ER+ | HER2- | PR- | 1 |
Her2 | ER+ | HER2- | PR+ | 3 |
Her2 | ER+ | HER2+ | PR- | 5 |
Her2 | ER+ | HER2+ | PR+ | 3 |
LumA | ER- | HER2- | PR- | 1 |
LumA | ER+ | HER2- | PR+ | 30 |
LumA | ER+ | HER2+ | PR+ | 9 |
LumB | ER- | HER2- | PR- | 1 |
LumB | ER+ | HER2- | PR+ | 36 |
LumB | ER+ | HER2+ | PR- | 4 |
LumB | ER+ | HER2+ | PR+ | 12 |